4-carboxy-4-phenylpyrolidin-2-one | 58024-63-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 4-carboxy-4-phenylpyrolidin-2-one
• 英文别名: 5-Oxo-3-phenyl-3-pyrrolidin-essigsaeure；5-Oxo-3-phenylpyrrolidine-3-carboxylic acid
• CAS: 58024-63-8
• 化学式: C₁₁H₁₁NO₃
• mdl: MFCD24481762
• 分子量: 205.213
• InChiKey: RXTMALRTSYUTGD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.272
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  苯基氰基乙酸乙酯 在 氢氧化钾 、 氢气 、 sodium ethanolate 、 镍 作用下， 以 乙醇 为溶剂， 25.0 ℃ 、101.33 kPa 条件下， 反应 1.0h， 生成 4-carboxy-4-phenylpyrolidin-2-one
  参考文献：
  名称：

  New pyrrolidin-, piperidin- and azepin-2-oxocarboxylic acid esters are preferential M1, M3 muscarinic antagonists. Synthesis and bronchospasmolytic activity

  摘要：

  A series of new 3-tropanol and 3-quinuclidinol esters of phenyl-substituted pyrrolidin-, piperidin- and azepin-2-oxocarboxylic acid were synthesized and tested for antimuscarinic activity. The compounds showed a preferential in vitro activity at M(1) and M(3) receptor subtypes and an interesting activity profile in vivo. A potential use as selective bronchospasmolytic agents has been suggested for selected compounds.

  DOI：

  10.1016/0223-5234(94)90068-x

文献信息

• [EN] INDANE DERIVATIVES AS MGLUR7 MODULATORS<br/>[FR] DÉRIVÉS D'INDANE UTILISÉS COMME MODULATEURS DE MGLUR7
  申请人：TAKEDA PHARMACEUTICALS CO

  公开号：WO2017131221A1

  公开（公告）日：2017-08-03

  The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a and R4b are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds of formula (I) are mGluR7 modulators.

  本发明提供了式（I）的化合物及其药学上可接受的盐，其中R1、R2、R3、R4a和R4b如规范中定义，其制备方法，含有它们的药物组合物以及它们在治疗中的用途。式（I）的化合物是mGluR7调节剂。
• INDANE DERIVATIVES AS MGLUR7 MODULATORS
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP3408256A1

  公开（公告）日：2018-12-05
• [EN] MODULATORS OF G-PROTEIN COUPLED RECEPTORS<br/>[FR] MODULATEURS DE RÉCEPTEURS COUPLÉS À LA PROTÉINE G
  申请人：[en]CARMOT THERAPEUTICS, INC.

  公开号：WO2022241287A2

  公开（公告）日：2022-11-17

  This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt) that modulate (e.g., agonize or partially agonize or antagonize) glucagonlike peptide-1 receptor ("GLP-1R") and/or the gastric inhibitory polypeptide receptor ("GIPR"). The chemical entities are useful, e.g., for treating a disease, disorder, or condition in which modulation (e.g., agonism, partial agonism or antagonism) of GLP-1R and/or GIPR activities is beneficial for the treatment or prevention of the underlying pathology and/or symptoms and/or progression of the disease, disorder, or condition. In some embodiments, modulation results in enhancement of (e.g., increases) existing levels (e.g., normal or below normal levels) of GLP-1R and/or GIPR activity (e.g., signaling). In some embodiments, the chemical entities described herein further modulate (e.g., attenuate, uncouple) β -arrestin signaling relative to what is observed with the native ligand. This disclosure also features compositions as well as other methods of using and making the said chemical entities.
• New pyrrolidin-, piperidin- and azepin-2-oxocarboxylic acid esters are preferential M1, M3 muscarinic antagonists. Synthesis and bronchospasmolytic activity
  作者：E Cereda、A Ezhaya、E Bellora、GB Schiavi、A Sagrada、HN Doods、A Donetti

  DOI：10.1016/0223-5234(94)90068-x

  日期：1994.1

  A series of new 3-tropanol and 3-quinuclidinol esters of phenyl-substituted pyrrolidin-, piperidin- and azepin-2-oxocarboxylic acid were synthesized and tested for antimuscarinic activity. The compounds showed a preferential in vitro activity at M(1) and M(3) receptor subtypes and an interesting activity profile in vivo. A potential use as selective bronchospasmolytic agents has been suggested for selected compounds.